Antiviral Efficacy of Pralatrexate against SARS-CoV-2.
Antiviral Efficacy of Pralatrexate against SARS-CoV-2.
复制标题
DOI：
10.4062/biomolther.2021.032
复制
发表时间：
2021-05-01
影响因子：
3.7
通讯作者：
Park MS
中科院分区：
文献类型：
--
作者：
Bae JY;Lee GE;Park H;Cho J;Kim J;Lee J;Kim K;Kim JI;Park MS
自2019年12月以来，新型冠状病毒（SARS-CoV-2）已造成1亿多例人类传染病（COVID-19）确诊病例，使我们的国际社会陷入瘫痪。然而，COVID-19疫苗和抗病毒治疗方案的获取有限。在这里，我们报告了抗癌药物普拉特雷酸对SARS-CoV-2的疗效。在Vero和人肺上皮Calu-3细胞中，普拉氨蝶呤减少了SARS-CoV-2的病毒RNA拷贝，而没有检测到细胞毒性，并且以剂量依赖的方式成功地抑制了病毒复制。在添加时间测定中，在感染后近半天使用普拉氨蝶呤也显示出对Calu-3细胞中SARS-CoV-2复制的抑制作用。综上所述，这些结果表明，普拉特雷酸有可能成为一种重新利用COVID-19治疗药物的药物。
Novel coronavirus (SARS-CoV-2) has caused more than 100 million confirmed cases of human infectious disease (COVID-19) since December 2019 to paralyze our global community. However, only limited access has been allowed to COVID-19 vaccines and antiviral treatment options. Here, we report the efficacy of the anticancer drug pralatrexate against SARS-CoV-2. In Vero and human lung epithelial Calu-3 cells, pralatrexate reduced viral RNA copies of SARS-CoV-2 without detectable cytotoxicity, and viral replication was successfully inhibited in a dose-dependent manner. In a time-to-addition assay, pralatrexate treatment at almost half a day after infection also exhibited inhibitory effects on the replication of SARS-CoV-2 in Calu-3 cells. Taken together, these results suggest the potential of pralatrexate as a drug repurposing COVID-19 remedy.